Medical Genetics Research Centre, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Department of Medical Immunology, Faculty of Medicine, Golestan University of Medical Sciences, Golestan, Iran.
Curr Pharm Biotechnol. 2020;21(14):1422-1432. doi: 10.2174/1389201021999200727163238.
Cancer is considered as the main public health problem and the second leading cause of morbidity and mortality worldwide. Numerous environmental-lifestyle related risk factors account for around one-third of cancer deaths. Recently, the key role of lncRNAs has been widely investigated in a variety of disorders, including cancer. The lncRNA GHET1 has been considered as an essential oncogenic lncRNA in many types of human cancers. Clinical investigations indicated that expression of lncRNA GHET1 is correlated with clinicopathological characteristics in cancer. This metaanalysis investigated the correlation between the lncRNA GHET1 expression and clinicopathological features in different types of cancers.
Comprehensive literature searches in PubMed, Scopus, and Web of Knowledge were conducted up to April 11, 2019. Sixteen studies were included in this meta-analysis. All statistical analyses were conducted using Stata software, version 12.0.
The pooled OR and 95%CIs of the sixteen relevant studies showed that over expression of lncRNA GHET1 was associated with tumor-size ≥5 cm (OR= 2.51, 95% CI: 1.89-3.33, p=0.00, I2=38.30%), positive lymph node metastasis (OR= 2.83, 95% CI: 1.78-4.52, p=0.00, I2=45.60%), advanced tumor stage (OR= 3.92, 95% CI: 2.97-5.19, p=0.00, I2=0.00%), positive distant metastasis (OR= 5.74, 95% CI: 2.58-12.77, p=0.00, I2=0.00%), advanced tumor status (OR= 2.97, 95% CI: 1.40- 6.29, p=0.01, I2=34.70%), and positive vascular invasion (OR= 2.69, 95% CI: 1.61-4.50, p=0.00, I2=29.20%).
Taken together, the current study demonstrated that overexpression of lncRNA GHET1 is significantly associated with clinicopathological features in human cancers. Our results suggested that lncRNA GHET1 can be utilized as a prognostic biomarker in human cancer.
癌症被认为是主要的公共卫生问题，也是全球发病率和死亡率的第二大主要原因。许多与环境-生活方式相关的风险因素占癌症死亡人数的三分之一左右。最近，lncRNAs 的关键作用已在多种疾病中得到广泛研究，包括癌症。lncRNA GHET1 已被认为是多种人类癌症中的重要致癌 lncRNA。临床研究表明，lncRNA GHET1 的表达与癌症的临床病理特征相关。这项荟萃分析研究了 lncRNA GHET1 表达与不同类型癌症的临床病理特征之间的相关性。
截至 2019 年 4 月 11 日，我们在 PubMed、Scopus 和 Web of Knowledge 中进行了全面的文献检索。这项荟萃分析纳入了 16 项相关研究。所有统计分析均使用 Stata 软件，版本 12.0 进行。
纳入的 16 项相关研究的合并 OR 和 95%CI 表明，lncRNA GHET1 过表达与肿瘤大小≥5cm（OR=2.51，95%CI：1.89-3.33，p=0.00，I2=38.30%）、阳性淋巴结转移（OR=2.83，95%CI：1.78-4.52，p=0.00，I2=45.60%）、晚期肿瘤分期（OR=3.92，95%CI：2.97-5.19，p=0.00，I2=0.00%）、阳性远处转移（OR=5.74，95%CI：2.58-12.77，p=0.00，I2=0.00%）、晚期肿瘤状态（OR=2.97，95%CI：1.40-6.29，p=0.01，I2=34.70%）和阳性血管浸润（OR=2.69，95%CI：1.61-4.50，p=0.00，I2=29.20%）显著相关。
综上所述，本研究表明 lncRNA GHET1 的过表达与人类癌症的临床病理特征显著相关。我们的结果表明，lncRNA GHET1 可以作为人类癌症的预后生物标志物。
